SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16 of the
Securities Exchange Act of 1934
For the month of September 2017
FRESENIUS MEDICAL CARE AG & Co. KGaA
(Translation of registrants name into English)
Else-Kröner Strasse 1
61346 Bad Homburg
Germany
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F x |
Form 40-F o |
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): o
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): o
Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes o |
No x |
If Yes is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
DATE: September 28, 2017 |
| ||
|
| ||
|
FRESENIUS MEDICAL CARE AG & Co. KGaA, | ||
|
a partnership limited by shares, represented by: | ||
|
| ||
|
FRESENIUS MEDICAL CARE MANAGEMENT AG, its | ||
|
general partner | ||
|
| ||
|
| ||
|
By: |
/s/ RICE POWELL | |
|
|
| |
|
|
Name: |
Rice Powell |
|
|
|
|
|
|
Title: |
Chief Executive Officer and |
|
|
|
Chairman of the Management Board |
|
|
|
of the General Partner |
|
| ||
|
| ||
|
By: |
/s/ MICHAEL BROSNAN | |
|
|
| |
|
|
Name: |
Michael Brosnan |
|
|
|
|
|
|
Title: |
Chief Financial Officer and |
|
|
|
Member of the Management Board |
|
|
|
of the General Partner |
Exhibit 99.1
Press Release |
Media Contact |
Matthias Link | |
T +49 6172 609-2872 | |
matthias.link@fresenius.com | |
| |
Contact for analysts and investors | |
Dr. Dominik Heger | |
T +49 6172 609-2601 | |
dominik.heger@fmc-ag.com | |
| |
www.freseniusmedicalcare.com |
September 28, 2017
Fresenius Medical Care divests Shiel Medical Laboratory to Quest Diagnostics
Fresenius Medical Care, the worlds largest provider of dialysis products and services, today announced the divestment of the business of Shiel Medical Laboratory, Inc. to Quest Diagnostics, Inc. Shiel provides comprehensive non-dialysis laboratory services in the New York-New Jersey metropolitan area.
The decision to divest Shiel is aligned with Fresenius Medical Cares goal to further optimize the Companys Care Coordination portfolio. Fresenius Medical Cares dialysis-related laboratory services business, Spectra Labs, is not affected by the divestiture.
The divestment is expected to generate a modest book gain for Fresenius Medical Care. Closing of the transaction is subject to regulatory approvals and anticipated in the fourth quarter of 2017.
The sale of Shiel Medical Laboratory will optimize the growth profile of our portfolio of Care Coordination activities in the U.S., said Rice Powell, Chief Executive Officer of Fresenius Medical Care. Based on the business development relative to our original expectations were keen to focus on areas offering superior growth and benefits for our core activities. With this transaction, Shiels customers will have access to even more diagnostic expertise. Ensuring a smooth transition will be a priority.
By joining forces with Shiel, physicians and patients in the New York-New Jersey region will have broader access to Quests diagnostic insights and innovations, said Steve Rusckowski, Quest Diagnostics Chairman, President and CEO. The acquisition will also deliver on Quests strategy to accelerate growth and drive operational excellence through strategically aligned, accretive acquisitions.
Fresenius Medical Care and Quest will also collaborate on identifying patients with early-stage chronic kidney disease, based on Quests laboratory data analytics, who may benefit from treatment to slow progression to end-stage renal disease (ESRD).
Fresenius Medical Care is the worlds largest provider of products and services for individuals with renal diseases of which around 3 million patients worldwide regularly undergo dialysis treatment. Through its network of 3,690 dialysis clinics, Fresenius Medical Care provides dialysis treatments for 315,305 patients around the globe. Fresenius Medical Care is also the leading provider of dialysis products such as dialysis machines or dialyzers. Along with the core business, the Company focuses on expanding the range of related medical services in the field of Care Coordination. Fresenius Medical Care is listed on the Frankfurt Stock Exchange (FME) and on the New York Stock Exchange (FMS).
For more information visit the Companys website at www.freseniusmedicalcare.com.
Disclaimer
This release contains forward-looking statements that are subject to various risks and uncertainties. Actual results could differ materially from those described in these forward-looking statements due to certain factors, including changes in business, economic and competitive conditions, regulatory reforms, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. These and other risks and uncertainties are detailed in Fresenius Medical Care AG & Co. KGaAs reports filed with the U.S. Securities and Exchange Commission. Fresenius Medical Care AG & Co. KGaA does not undertake any responsibility to update the forward-looking statements in this release.